Menopause causes profound biological changes that directly affect the skin. Yet, these changes remain under-recognised in dermatology and aesthetic practice. At IMCAS 2026 in Paris, Galderma addressed this gap with new global survey data on clinical trial inclusivity.
Global survey reveals common skin concerns
Galderma presented findings from a global survey involving more than 4,300 peri- and post-menopausal women. The participants were aged 45 to 60 and had experience with, or interest in, aesthetic treatments. The results confirmed that menopause significantly alters skin quality, appearance, and patient confidence.
Women reported experiencing an average of three skin changes during menopause. The most common concern was lines and wrinkles, affecting both the face and body. Loss of firmness and elasticity followed closely, reflecting hormonal declines in collagen and elastin. Dryness and dull skin tone were also widely reported, reinforcing the multifactorial impact of oestrogen loss.
Knowledge gaps affect patient awareness
Despite the prevalence of these symptoms, awareness remains low. More than half of respondents learnt about menopause-related skin changes only after experiencing them personally. Many women stated they would have preferred education earlier in life, ideally during their 30s. Overall knowledge satisfaction scores remained modest, highlighting an education gap clinicians can address.
Beyond physical changes, the survey revealed significant emotional consequences. Many women reported feeling less attractive and less confident. Anxiety levels increased, and social engagement declined for a notable proportion. These findings emphasise that menopausal skin changes affect psychological wellbeing, not just aesthetics.
For dermatologists, this reinforces the importance of proactive conversations. Menopause should become a routine consideration during midlife skin assessments. Early counselling can improve trust, set realistic expectations, and support long-term treatment planning.
Practical implications for dermatology practice
Importantly, Galderma announced a strategic shift in its research approach. The company will now record menopausal status across all injectable aesthetics clinical trials. This move aims to generate more representative data and clarify how hormonal changes influence treatment outcomes. Clinical trials have traditionally grouped women by age alone. This approach often overlooks hormonal status, which can significantly alter skin physiology and response to treatment. By capturing menopausal status, Galderma aims to provide clinicians with more precise, evidence-based insights.
At IMCAS, Galderma reinforced this commitment through its symposium, “Menopause in the Mirror: Challenges, Science and Aesthetic Solutions”. Experts discussed biological mechanisms, patient communication, and aesthetic strategies tailored to menopausal skin. Live demonstrations further connected research with real-world practice.
This initiative signals a broader industry shift. Menopause is moving from a peripheral discussion to a defined clinical consideration. Brands, clinicians, and researchers now share responsibility for advancing education and inclusive evidence. Dermatology practices can respond by integrating menopause into consultations, treatment plans, and patient education materials. Doing so strengthens clinical outcomes and deepens patient relationships.
Important step forward
Galderma’s data and trial strategy represent an important step forward. Menopausal skin deserves targeted research, informed dialogue, and thoughtful clinical care. The opportunity now lies in translating insight into everyday practice.